XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 46.905

Change

-1.25 (-2.59)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-21 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.74 (-1.42%)

USD 128.40B
SXR8:F iShares Core S&P 500 UCITS ETF..

-13.56 (-2.41%)

USD 114.04B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.79 (-1.38%)

USD 96.03B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.23 (-1.47%)

USD 57.02B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 53.72B
SXRZ:F iShares VII PLC - iShares Nikk..

-3.60 (-1.55%)

USD 52.44B
VUSA:F Vanguard Funds Public Limited ..

-1.29 (-1.30%)

USD 51.63B
0ZC:F Zscaler Inc

-3.30 (-1.48%)

USD 37.92B
BSND:F Danone SA

+0.20 (+1.39%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

-1.66 (-1.29%)

USD 24.77B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.72% 10% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.72% 10% F 29% F
Trailing 12 Months  
Capital Gain -13.68% 11% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.68% 10% F 31% F
Trailing 5 Years  
Capital Gain 27.72% 39% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.72% 39% F 34% F
Average Annual (5 Year Horizon)  
Capital Gain 9.96% 71% C- 66% D+
Dividend Return 9.96% 69% C- 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.98% 61% D- 89% A-
Risk Adjusted Return 90.69% 86% B+ 89% A-
Market Capitalization 0.85B 70% C- 55% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike